Advisories For Registrants
June 17th, 2024
Dianeal PD4 2.5% Dextrose and Physioneal 40 2.27% Glucose peritoneal dialysis solutions recalled due to risk of leakage at connection site
June 10th, 2024
Important Safety and Efficacy Information on ALBRIOZA (sodium phenylbutyrate and ursodoxicoltaurine) – Market Withdrawal and Continued Restricted Access
June 6th, 2024
Importation of USA-authorized Carbamazepine Extended-Release Tablets, USP 200 mg and 400 mg due to the current shortage of Canadian-authorized carbamazepine
Advisories For The Public
August 5th, 2024
Expanded recall: ratio-ECTOSONE (TEVA-ECTOSONE) 0.1% regular lotion and 0.05% mild lotion recalled due to an impurity that may pose health risks
August 5th, 2024
JAMP Digoxin 0.0625 mg and 0.125 mg tablets recalled due to possible incorrect dose, which may pose health risks
July 29th, 2024
Various multivitamins and supplements distributed across Canada are being recalled because they may contain metal fibres
July 26th, 2024
Incorrect dosing information on the “SAVE ME” instructional card in the Naloxone Take Home Kit by Canadian Hospital Specialties Ltd
June 17th, 2024
Dianeal PD4 2.5% Dextrose and Physioneal 40 2.27% Glucose peritoneal dialysis solutions recalled due to risk of leakage at connection site
June 10th, 2024
Accel-Ondansetron ODT, Mint-Betahistine and PMS-Pirfenidone tablets recalled due to data integrity concerns
NL pharmacist & physicians join forces working towards reducing opioid prescribing:
The Canadian Federation of College Physicians (CFCP) and the Canadian Pharmacist Association partnered to highlight examples of noteworthy professional practice through collaboration between pharmacists and physicians. In CFCP’s Innovation in Primary Care series, April 2019 edition, check out the exemplary patient care efforts taking place right here in Newfoundland & Labrador at the Shea Heights Community Health Centre (SHCHC) – It Takes a Team: Caring for patients taking opioids for chronic non-cancer pain.
Through interdisciplinary collaboration, the professional staff at the SHCHC used standardized processes to make opioid prescribing more safe and manageable. This model supports the Board’s vision, and aligns with the Code of Ethics (#8), as it promotes registrants working with their colleagues and other health care professionals to optimize patient centred-care. This specific model illustrates how pharmacists and physicians can team up to enhance patients’ pain therapy and reduce potential harms related to opioid prescribing.
If you work in an interdisciplinary practice environment, this model might work for you! The Board encourages registrants to collaborate with colleagues to create opportunities and provide solutions for optimizing patient care.
